Polypharmacy: a healthcare conundrum with a pharmacogenetic solution

References

• Barto TG. Which Drugs Should Be Deprescribed in the Elderly? MedScape. 2015 [cited 2019 Apr 2]. Available from: https://www.medscape.com/viewarticle/847187_2
   Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
   PubMed Web of Science ®Google Scholar
• Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428–437.
   PubMed Web of Science ®Google Scholar
• Schmidt I, Claesson CB, Westerholm B, et al. The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. J Am Geriatr Soc. 1998;46(1):77–82.
   PubMed Web of Science ®Google Scholar
• Tamura BK, Bell CL, Lubimir K, et al. Physician intervention for medication reduction in a nursing home: the polypharmacy outcomes project. J Am Med Dir Assoc. 2011;12(5):326–330.
   PubMed Web of Science ®Google Scholar
• Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–351.
   PubMedGoogle Scholar
• Lipton HL, Bird JA. The impact of clinical pharmacists' consultations on geriatric patients' compliance and medical care use: a randomized controlled trial. Gerontologist. 1994;34(3):307–315.
   PubMed Web of Science ®Google Scholar
• Swinglehurst D, Fudge N. The polypharmacy challenge: time for a new script? Br J Gen Pract. 2017;67(662):388–389.
   PubMed Web of Science ®Google Scholar
• Quinn KJ, Shah NH. A dataset quantifying polypharmacy in the United States. Sci Data. 2017;4(1):170167.
   PubMedGoogle Scholar
• Vu T, Finch CF, Day L. Patterns of comorbidity in community-dwelling older people hospitalised for fall-related injury: a cluster analysis. BMC Geriatr. 2011;11(1):45.
   PubMedGoogle Scholar
• Fillenbaum GG, Pieper CF, Cohen HJ, et al. Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality. J Gerontol A Biol Sci Med Sci. 2000;55(2):M84–M89.
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J Psychopharmacol. 2006;20(4_suppl):85–94.
   PubMedGoogle Scholar
• Saper RB. Clinical Use of Gingko Biloba. 2018 [updated 7/28/2018; cited 2019. 2/18/2019].
   Google Scholar
• Stoddard GJ, Archer M, Shane-McWhorter L, et al. Ginkgo and Warfarin Interaction in a large veterans administration population. AMIA Annu Symp Proc. 2015;2015:1174–1183.
   PubMedGoogle Scholar
• Medhekar R, Fujimoto K, Aparasu RR, et al. Physician care coordination and the use of psychotropic polypharmacy in the management of pediatric mental disorders. JMCP. 2019;25(1):29–38.
   PubMed Web of Science ®Google Scholar
• Baker C, Feinstein JA, Ma X, et al. Variation of the prevalence of pediatric polypharmacy: a scoping review. Pharmacoepidemiol Drug Saf. 2019;28(3):275–287.
   PubMed Web of Science ®Google Scholar
• Zonfrillo MR, Penn JV, Leonard HL. Pediatric psychotropic polypharmacy. Psychiatry (Edgmont). 2005;2(8):14–19.
   PubMedGoogle Scholar
• Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17–25.
   PubMed Web of Science ®Google Scholar
• Martin A, Van Hoof T, Stubbe D, et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. PS. 2003;54(1):72–77.
   Google Scholar
• Deza EG, Morgenfeld EL, Rivarola EGJ, et al. Polypharmacy in oncology patients. JCO. 2014;32(15_suppl):e17582–e17582.
   Google Scholar
• Molas E, Luque S, Retamero A, et al. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients identified through a multidisciplinary team. HIV Clin Trials. 2018;19(1):1–7.
   PubMed Web of Science ®Google Scholar
• Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of Antiretroviral Therapy (ART) among HIV patients. AIDS Patient Care STDS. 2016;30(1):11–17.
   PubMed Web of Science ®Google Scholar
• Ware D, Palella FJ Jr, Chew KW, et al. Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016. PLoS One. 2018;13(9):e0203890.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Fullington HM, Alvarez CA, et al. Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer. 2018;124(13):2850–2857.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry: Consumer-Directed Broadcast Advertisements. 1999.
   Google Scholar
• Kornfield R, Donohue J, Berndt ER, et al. Promotion of prescription drugs to consumers and providers, 2001–2010. PLoS One. 2013;8(3):e55504.
   PubMed Web of Science ®Google Scholar
• Trusts PC. Persuading the Prescribers: Pharmaceutical Industry Marketing and its Influence on Physicians and Patients. 2013 [cited 2014 Feb 8]. Available from: https://www.pewtrusts.org/en/research-and-ana lysis/fact-sheets/2013/11/11/persuading-the-prescribe rs-pharmaceutical-industry-marketing-and-its-influenc e-on-physicians-and-patients
   Google Scholar
• Gilbody S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care. 2005;14(4):246–250.
   PubMedGoogle Scholar
• FDA. Office of Prescription Drug Promotion (OPDP) Research. [cited 2014 Feb 8]. Available from: https://www.fda.gov/AboutFDA/CentersOffices/Officeof MedicalProductsandTobacco/CDER/ucm090276.htm
   Google Scholar
• Alexander GC, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. JAMA. 2012;308(18):1865–1866.
   PubMed Web of Science ®Google Scholar
• McKinlay JB, Trachtenberg F, Marceau LD, et al. Effects of patient medication requests on physician prescribing behavior: results of a factorial experiment. Med Care. 2014;52(4):294–299.
   PubMed Web of Science ®Google Scholar
• Fain KM, Alexander GC. Mind the gap: understanding the effects of pharmaceutical direct-to-consumer advertising. Med Care. 2014;52(4):291–293.
   PubMed Web of Science ®Google Scholar
• Frosch DL, Grande D, Tarn DM, et al. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. Am J Public Health. 2010;100(1):24–32.
   PubMed Web of Science ®Google Scholar
• Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995–2002.
   PubMed Web of Science ®Google Scholar
• Davies EC, Green CF, Mottram DR, et al. Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther. 2006;31(4):335–341.
   PubMed Web of Science ®Google Scholar
• Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int. 2012;12(4):761–762.
   PubMed Web of Science ®Google Scholar
• Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356(9242):1667–1671.
   PubMed Web of Science ®Google Scholar
• Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med. 1999;159(21):2553–2560.
   PubMedGoogle Scholar
• Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012;28(2):173–186.
   PubMed Web of Science ®Google Scholar
• Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):666–671.
   PubMed Web of Science ®Google Scholar
• Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.
   PubMedGoogle Scholar
• Pirmohamed M, Breckenridge AM, Kitteringham NR, et al. Adverse drug reactions. *BMJ. 1998;316(7140):1295–1298.
   PubMed Web of Science ®Google Scholar
• Carmona-Huerta J, Castiello-de Obeso S, Ramirez-Palomino J, et al. Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification. BMC Psychiatry. 2019;19(1):78.
   PubMedGoogle Scholar
• McIsaac DI, Wong CA, Bryson GL, et al. Association of polypharmacy with survival, complications, and healthcare resource use after elective noncardiac surgery: a population-based cohort study. Anesthesiology. 2018;128(6):1140–1150.
   PubMed Web of Science ®Google Scholar
• Sikka R, Magauran B, Ulrich A, et al. Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad Emerg Med: Off J Soc Acad Emerg Med. 2005;12(12):1227–1235.
   PubMed Web of Science ®Google Scholar
• Haider SI, Johnell K, Thorslund M, et al. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. CP. 2007;45(12):643–653.
   Google Scholar
• Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug–drug interactions with a prescription claims database. Am J Health Syst Pharm. 2005;62(19):1983–1991.
   PubMed Web of Science ®Google Scholar
• Carpenter M, Berry H, Pelletier AL. Clinically relevant drug–drug interactions in primary care. Am Fam Physician. 2019;99(9):558–564.
   PubMed Web of Science ®Google Scholar
• Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13(1):74.
   PubMed Web of Science ®Google Scholar
• Kalisch LM, Caughey GE, Roughead EE, et al. The prescribing cascade. Aust Prescr. 2011;34(6):162–166.
   Web of Science ®Google Scholar
• Nguyen PV, Spinelli C. Prescribing cascade in an elderly woman. Can Pharm J. 2016;149(3):122–124.
   Web of Science ®Google Scholar
• Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808–813.
   PubMedGoogle Scholar
• Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug expenditure – a register-based study in Sweden 2005–2009. Health Policy. 2013;109(2):166–174.
   PubMed Web of Science ®Google Scholar
• Hovstadius B, Astrand B, Persson U, et al. Acquisition cost of dispensed drugs in individuals with multiple medications – a register-based study in Sweden. Health Policy. 2011;101(2):153–161.
   PubMed Web of Science ®Google Scholar
• Kojima G, Bell C, Tamura B, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc. 2012;13(9):818–e11-815.
   PubMed Web of Science ®Google Scholar
• Stevenson FA, Barry CA, Britten N, et al. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med. 2000;50(6):829–840.
   PubMed Web of Science ®Google Scholar
• Sihvo S, Klaukka T, Martikainen J, et al. Frequency of daily over-the-counter drug use and potential clinically significant over-the-counter-prescription drug interactions in the Finnish adult population. Eur J Clin Pharmacol. 2000;56(6–7):495–499.
   PubMed Web of Science ®Google Scholar
• Schafer I, Kaduszkiewicz H, Mellert C, et al. Narrative medicine-based intervention in primary care to reduce polypharmacy: results from the cluster-randomised controlled trial MultiCare AGENDA. BMJ Open. 2018;8(1):e017653.
   PubMed Web of Science ®Google Scholar
• Radcliff S, Yue JR, Rocco G, et al. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.
   PubMed Web of Science ®Google Scholar
• Steinman MA, Fick DM. Using wisely: a reminder on the proper use of the American Geriatrics Society Beers Criteria (R). J Am Geriatr Soc. 2019;67(4):644–646.
   PubMed Web of Science ®Google Scholar
• By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–694.
   PubMed Web of Science ®Google Scholar
• King MA, Roberts MS. Multidisciplinary case conference reviews: improving outcomes for nursing home residents, carers and health professionals. Pharm World Sci. 2001;23(2):41–45.
   PubMed Web of Science ®Google Scholar
• Muth C, Blom JW, Smith SM, et al. Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus. J Intern Med. 2019;285(3):272–288.
   PubMed Web of Science ®Google Scholar
• Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520(7549):609–611.
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
   PubMed Web of Science ®Google Scholar
• Linder MW, Valdes R Jr. Fundamentals of pharmacogenetics. In: Wong SHY LM, Valdes R Jr, editors. Pharmacogenomics and proteomics: enabling the practice of personalized medicine. Washington, DC: AACC Press; 2006.
   Google Scholar
• Milone MC, Shaw LM. Therapeutic drugs and their management. Tietz textbook of clinical chemistry and molecular diagnostics. New York: Elsevier; 2006.
   Google Scholar
• Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet. 2001;2(12):930–942.
   PubMed Web of Science ®Google Scholar
• Linder MW, Valdes R Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol. 2001;25(5):405–413.
   PubMed Web of Science ®Google Scholar
• Burtis CA, Bruns DE. Pharmacogenetics. In: Sawyer BG, editor. Tietz fundamentals of clinical chemistry and molecular diagnostics. New York: Elsevier; 2015. p. 885–898.
   Google Scholar
• Valdes R Jr, Payne DA, Linder MW. Laboratory analysis and application of pharmacogenetics to clinical practice: National Academy of Clinical Biochemistry; 2010. Available from: https://www.aacc.org/∼/media/practice-guidelines/pharmacogenetics/pgx_guidelines.pdf?la=en
   Google Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–2221.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359(8):789–799.
   PubMed Web of Science ®Google Scholar
• Li JH, Suchindran S, Shah SH, et al. SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. Pharmacogenomics. 2015;16(5):449–458.
   PubMed Web of Science ®Google Scholar
• Picard N, Bergan S, Marquet P, et al. Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs. Ther Drug Monit. 2016;38(Suppl 1):S57–S69.
   PubMed Web of Science ®Google Scholar
• Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing “side effects” of pharmaceuticals on society and the environment. Sci Total Environ. 2013;443:324–337.
   PubMed Web of Science ®Google Scholar
• Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol. 2006;58(7):871–885.
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Kirchheiner J, Meisel C, et al. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics. 2000;1(2):125–151.
   PubMedGoogle Scholar
• Linder MW, Valdes R Jr. Pharmacogenetics in the practice of laboratory medicine. Mol Diagn: A J Devoted Understanding Hum Dis Clin Appl Mol Biol. 1999;4(4):365–379.
   Google Scholar
• Reynolds KK, Valdes R Jr, Hartung BR, et al. Individualizing warfarin therapy. Per Med. 2007;4(1):11–31.
   PubMed Web of Science ®Google Scholar
• Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91(1):87–94.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–2303.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41.
   PubMed Web of Science ®Google Scholar
• Rouse M, Cristiani C, Teng KA. Q: should we use pharmacogenetic testing when prescribing warfarin? Cleve Clin J Med. 2013;80(8):483–486.
   PubMed Web of Science ®Google Scholar
• Simon T, Danchin N. Clinical impact of pharmacogenomics of clopidogrel in stroke. Circulation. 2017;135(1):34–37.
   PubMed Web of Science ®Google Scholar
• Pan Y, Chen W, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135(1):21–33.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Baumann P, Bergemann N, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195–235.
   Web of Science ®Google Scholar
• Finkelstein J, Friedman C, Hripcsak G, et al. Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study. PGPM. 2016;9:107–116.
   Google Scholar
• Isidoro-Garcia M, Sanchez-Martin A, Garcia-Berrocal B, et al. Primun non nocere, polypharmacy and pharmacogenetics. Pharmacogenomics. 2015;16(17):1903–1905.
   PubMed Web of Science ®Google Scholar
• Saldivar JS, Taylor D, Sugarman EA, et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility. Pharmgenomics Pers Med. 2016;9:1–6.
   PubMed Web of Science ®Google Scholar
• Mayhew M, Jablonski M, Li J, et al. Combinatorial Pharmacogenomics Reduces Polypharmacy and Medication Cost in Elderly Patients with Anxiety and Depression. AAGP Annual Meeting2017.
   Google Scholar
• Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17(5):395–402.
   PubMed Web of Science ®Google Scholar
• Johnson SG, Gruntowicz D, Chua T, et al. Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention. JMCP. 2015;21(7):552–557.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Humma LM. Pharmacogenetics of cardiovascular drugs. Brief Funct Genomics Proteomics. 2002;1(1):66–79.
   PubMedGoogle Scholar
• Brixner D, Biltaji E, Bress A, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19(3):213–228.
   PubMed Web of Science ®Google Scholar
• Haga SB, Allen LaPointe NM, Moaddeb J. Challenges to integrating pharmacogenetic testing into medication therapy management. JMCP. 2015;21(4):346–352.
   PubMed Web of Science ®Google Scholar
• de Leon J, Spina E. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy? Expert Rev Clin Pharmacol. 2016;9(3):351–354.
   PubMed Web of Science ®Google Scholar
• Rahmner PB, Eiermann B, Korkmaz S, et al. Physicians' reported needs of drug information at point of care in Sweden. Br J Clin Pharmacol. 2012;73(1):115–125.
   PubMed Web of Science ®Google Scholar
• van der Wouden CH, Bank PCD, Ozokcu K, et al. Pharmacist-initiated Pre-emptive Pharmacogenetic Panel Testing with clinical decision support in primary care: record of PGx results and real-world impact. Genes (Basel). 2019;10(6):416.
   Web of Science ®Google Scholar
• Sim SC, Altman RB, Ingelman-Sundberg M. Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Hum Mutat. 2011;32(5):526–531.
   PubMed Web of Science ®Google Scholar
• PharmaADME [Internet]. [cited 2019 May 23]. Available from: http://www.pharmaadme.org/joomla/
   Google Scholar
• The Drug Gene Interaction Database [Internet]. [cited 5/23/2019. Available from: http://www.dgidb.org/
   Google Scholar
• Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017;78(06):720–729.
   PubMedGoogle Scholar